Positioning political buying, disclosed 2026-09-25
Options put/call open interest 0.64, read 2026-11-07
Ethical passes the values gate
Price452.80 USD
Fair value380.97
Ethical score74.5/100
Value readOvervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-11-03Read Markup436.87+3.6% to today ✓Accumulation gives way to Markup after an 8% rise in 3 weeks
2026-10-11Read Accumulation405.18+11.8% to today ✓Markup gives way to Accumulation after an 8% rise in 7 weeks
2026-08-22Read Markup374.48+20.9% to today ✓Distribution gives way to Markup after an 11% slide in 7 weeks
2026-07-02Read Distribution422.06+7.3% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Intuitive Surgical holds its Markup at $452.80. Consolidating, no directional conviction, held for 50 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 50 days
Price at the screen
$452.80
Valuation
54.26 trailing · 36.04 forward price to earnings
Values screen
PASS· score 74.5
Beta
1.46
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.30%
Below 33%
Interest-bearing debt is just 12.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
15.15%
Below 33%
Cash held in interest-bearing accounts and securities is 15.1% of assets, under the one-third limit.
Pass
Receivables
23.93%
Below 49%
Money owed to the company is 23.9% of assets, under the 49% limit.
Pass
Revenue purity
3.64%
Below 5%
Only 3.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Intuitive Surgical clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 12%, inside the ~33% line, and interest is about 4% of its income, under the ~5% line, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ISRG's ethical verdict changes
Today ISRG passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 6 Nov 2026: it trades above our $380.97 fair value estimate, moderate competitive moat, 21.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 18.9% above the base estimate.
Third-party analyst targets: 30 covering, consensus Buy. The average target sits +8% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $380.97, with a range of $291.60 to $438.12, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 36.0x forward earnings, the price already runs ahead of the business. It trades 19% above our $380.97 fair value, so you would be buying at a premium, not a discount. The moderate moat is real, but quality alone does not make an expensive price cheap.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ISRG trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markup · changed$436.87+2.1%Entry 21
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573.
2026-10-27Accumulation$427.86+0.0%Entry 20
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573.
2026-10-20Accumulation$427.86+0.0%Entry 19
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Accumulation$427.86+0.0%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$427.86+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Accumulation$427.86+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Accumulation$427.86+0.9%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Accumulation$423.96+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Accumulation$423.96+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-13Accumulation$423.96+4.6%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 22%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (30 analysts) rates it buy, with a mean price target of $573. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.